source
- Karyopharm stock tumbles after Phase 3 Xpovio trial fails in endometrial cancerKaryopharm announced that its Phase 3 XPORT-EC-042 study of Xpovio in endometrial cancer did not meet its primary endpoint. The failure represents the company's second unsuccessful attempt to expa…
- Latigo Biotherapeutics reports non-opioid drug cuts acute pain in Phase 2b trialLatigo Biotherapeutics announced that its experimental non-opioid analgesic demonstrated a reduction in acute pain in a Phase 2b clinical trial. The study results suggest the candidate may offer a…